408 related articles for article (PubMed ID: 19450754)
1. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
[TBL] [Abstract][Full Text] [Related]
2. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
3. Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
Taimur S; Askar M; Sobecks R; Rybicki L; Warshawsky I; Mossad S
Transpl Infect Dis; 2014 Feb; 16(1):61-6. PubMed ID: 24251680
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Parikh CR; Schrier RW; Storer B; Diaconescu R; Sorror ML; Maris MB; Maloney DG; McSweeney P; Storb R; Sandmaier BM
Am J Kidney Dis; 2005 Mar; 45(3):502-9. PubMed ID: 15754272
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
[TBL] [Abstract][Full Text] [Related]
9. Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.
Schaenman JM; Shashidhar S; Rhee C; Wong J; Navato S; Wong RM; Ho DY; Arai S; Johnston L; Brown JM
Biol Blood Marrow Transplant; 2011 May; 17(5):693-702. PubMed ID: 20736077
[TBL] [Abstract][Full Text] [Related]
10. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
11. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
[TBL] [Abstract][Full Text] [Related]
12. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
Fukuda T; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Martin PJ; Storb RF; Marr KA
Blood; 2003 Aug; 102(3):827-33. PubMed ID: 12689933
[TBL] [Abstract][Full Text] [Related]
13. Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
Travi G; Pergam SA; Xie H; Boeckh MJ
Biol Blood Marrow Transplant; 2009 Jun; 15(6):758-60. PubMed ID: 19450762
[No Abstract] [Full Text] [Related]
14. Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.
Huang YT; Su Y; Kim SJ; Nichols P; Burack D; Maloy M; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2019 Apr; 25(4):791-799. PubMed ID: 30476551
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.
Slade M; Goldsmith S; Romee R; DiPersio JF; Dubberke ER; Westervelt P; Uy GL; Lawrence SJ
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 28030755
[TBL] [Abstract][Full Text] [Related]
18. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
Junghanss C; Storb R; Maris MB; Carter RA; Sandmaier BM; Maloney DG; McSweeney PA; Corey L; Boeckh M
Br J Haematol; 2003 Nov; 123(4):662-70. PubMed ID: 14616970
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
[TBL] [Abstract][Full Text] [Related]
20. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]